Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

PURPOSE: Alhough antiangiogenic agents are the bedrock of treatment for radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), novel antiangiogenic agents with optimized features like greater target-binding affinities and more favorable pharmacokinetics profile are needed. This phase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Yihebali, Zheng, Xiangqian, Zhang, Yuan, Shi, Feng, Cheng, Ying, Guo, Zhuming, Ge, Minghua, Qin, Jianwu, Zhang, Jiewu, Li, Zhendong, Zhou, Xiaohong, Huang, Rui, Chen, Xiaohong, Liu, Hui, Cheng, Ruochuan, Xu, Zhengang, Li, Dapeng, Tang, Pingzhang, Gao, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570678/
https://www.ncbi.nlm.nih.gov/pubmed/37594724
http://dx.doi.org/10.1158/1078-0432.CCR-22-3406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570678/
https://www.ncbi.nlm.nih.gov/pubmed/37594724
http://dx.doi.org/10.1158/1078-0432.CCR-22-3406

Ejemplares similares